Literature DB >> 9472852

Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression.

M O'Connor, H Silver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9472852     DOI： 10.1097/00004714-199802000-00018

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  7 in total

Review 1.  Bipolar depression: management options.

Authors:  Gin S Malhi; Philip B Mitchell; Shahzad Salim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04       Impact factor: 5.270

3.  An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression.

Authors:  Ashwin A Patkar; Kathleen Peindl; Rajnish Mago; Paolo Mannelli; Prakash S Masand
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 4.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

5.  Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex.

Authors:  Mei Huang; Junji Ichiwaka; Zhu Li; Jin Dai; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2006-03-07       Impact factor: 4.530

6.  Off-label indications for atypical antipsychotics: A systematic review.

Authors:  Konstantinos N Fountoulakis; Ioannis Nimatoudis; Apostolos Iacovides; George Kaprinis
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-02-18

7.  A review of quetiapine in combination with antidepressant therapy in patients with depression.

Authors:  Ella J Daly; Madhukar H Trivedi
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.